tiprankstipranks
Trending News
More News >
OSE Immunotherapeutics SA (FR:OSE)
:OSE
France Market

OSE Immunotherapeutics SA (OSE) Ratios

Compare
12 Followers

OSE Immunotherapeutics SA Ratios

FR:OSE's free cash flow for Q2 2025 was €0.00. For the 2025 fiscal year, FR:OSE's free cash flow was decreased by € and operating cash flow was €-12.46. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
2.87 3.46 1.62 2.29 2.64
Quick Ratio
2.87 3.46 1.62 2.29 2.64
Cash Ratio
1.31 0.83 0.99 1.57 2.00
Solvency Ratio
-0.59 0.68 -0.33 -0.24 -0.26
Operating Cash Flow Ratio
-1.86 2.40 -1.05 -1.12 -0.59
Short-Term Operating Cash Flow Coverage
-5.85 6.22 -3.09 -5.90 -6.16
Net Current Asset Value
€ 2.05M€ 9.78M€ -28.60M€ -21.92M€ -9.78M
Leverage Ratios
Debt-to-Assets Ratio
0.37 0.37 0.56 0.49 0.37
Debt-to-Equity Ratio
0.76 0.72 2.01 1.38 0.78
Debt-to-Capital Ratio
0.43 0.42 0.67 0.58 0.44
Long-Term Debt-to-Capital Ratio
0.37 0.36 0.61 0.53 0.39
Financial Leverage Ratio
2.06 1.94 3.60 2.82 2.14
Debt Service Coverage Ratio
-3.23 3.50 -1.99 -2.24 -4.06
Interest Coverage Ratio
-13.74 13.25 -10.13 -17.52 -26.28
Debt to Market Cap
0.33 0.28 0.50 0.33 0.17
Interest Debt Per Share
1.89 2.27 2.46 2.50 2.09
Net Debt to EBITDA
-0.39 0.71 -1.55 -1.22 -0.24
Profitability Margins
Gross Profit Margin
40.02%100.00%100.00%100.00%100.00%
EBIT Margin
-1746.56%54.14%-944.14%-90.97%-62.26%
EBITDA Margin
-1591.92%58.95%-785.86%-85.68%-55.71%
Operating Profit Margin
-1999.72%62.59%-1032.15%-131.34%-83.53%
Pretax Profit Margin
-1813.42%57.00%-1042.70%-128.15%-81.95%
Net Profit Margin
-1617.22%53.59%-1032.91%-97.04%-64.05%
Continuous Operations Profit Margin
-1617.22%53.59%-1032.91%-97.04%-64.05%
Net Income Per EBT
89.18%94.01%99.06%75.72%78.16%
EBT Per EBIT
90.68%91.08%101.02%97.57%98.11%
Return on Assets (ROA)
-33.44%30.21%-28.03%-19.37%-16.60%
Return on Equity (ROE)
-60.89%58.68%-100.80%-54.57%-35.45%
Return on Capital Employed (ROCE)
-50.81%42.16%-36.34%-31.88%-25.92%
Return on Invested Capital (ROIC)
-42.23%36.67%-32.29%-22.93%-19.71%
Return on Tangible Assets
-56.78%46.84%-64.52%-41.41%-33.43%
Earnings Yield
-33.14%23.95%-27.47%-14.42%-9.03%
Efficiency Ratios
Receivables Turnover
0.18 16.89 1.23 0.00 34.08
Payables Turnover
0.09 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.53 20.40 0.55 3.68 4.84
Asset Turnover
0.02 0.56 0.03 0.20 0.26
Working Capital Turnover Ratio
0.05 2.28 0.14 0.76 0.99
Cash Conversion Cycle
-1.97K 21.61 295.84 0.00 10.71
Days of Sales Outstanding
1.98K 21.61 295.84 0.00 10.71
Days of Inventory Outstanding
0.00 0.00 0.00 0.00 0.00
Days of Payables Outstanding
3.95K 0.00 0.00 0.00 0.00
Operating Cycle
1.98K 21.61 295.84 0.00 10.71
Cash Flow Ratios
Operating Cash Flow Per Share
-1.64 2.22 -1.01 -0.99 -0.55
Free Cash Flow Per Share
-1.64 2.22 -1.02 -1.00 -0.57
CapEx Per Share
<0.01 <0.01 0.01 0.01 0.03
Free Cash Flow to Operating Cash Flow
1.00 1.00 1.01 1.02 1.05
Dividend Paid and CapEx Coverage Ratio
-531.99 629.09 -85.19 -66.61 -21.01
Capital Expenditure Coverage Ratio
-531.99 629.09 -85.19 -66.61 -21.01
Operating Cash Flow Coverage Ratio
-0.94 1.05 -0.43 -0.41 -0.27
Operating Cash Flow to Sales Ratio
-16.79 0.69 -8.87 -1.00 -0.38
Free Cash Flow Yield
-33.98%30.93%-23.88%-15.04%-5.57%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
-3.02 4.18 -3.64 -6.94 -11.08
Price-to-Sales (P/S) Ratio
49.51 2.24 37.60 6.73 7.09
Price-to-Book (P/B) Ratio
2.08 2.45 3.67 3.79 3.93
Price-to-Free Cash Flow (P/FCF) Ratio
-2.94 3.23 -4.19 -6.65 -17.96
Price-to-Operating Cash Flow Ratio
-2.91 3.23 -4.24 -6.75 -18.82
Price-to-Earnings Growth (PEG) Ratio
0.02 -0.02 -0.16 -2.15 0.90
Price-to-Fair Value
2.08 2.45 3.67 3.79 3.93
Enterprise Value Multiple
-3.50 4.51 -6.33 -9.08 -12.98
Enterprise Value
119.92M 185.75M 110.86M 142.38M 190.19M
EV to EBITDA
-3.50 4.51 -6.33 -9.08 -12.98
EV to Sales
55.67 2.66 49.78 7.78 7.23
EV to Free Cash Flow
-3.31 3.84 -5.54 -7.69 -18.30
EV to Operating Cash Flow
-3.32 3.83 -5.61 -7.80 -19.17
Tangible Book Value Per Share
0.35 0.91 -1.20 -0.88 -0.20
Shareholders’ Equity Per Share
2.29 2.93 1.17 1.76 2.62
Tax and Other Ratios
Effective Tax Rate
0.11 0.06 <0.01 0.24 0.22
Revenue Per Share
0.10 3.20 0.11 0.99 1.45
Net Income Per Share
-1.57 1.72 -1.18 -0.96 -0.93
Tax Burden
0.89 0.94 0.99 0.76 0.78
Interest Burden
1.04 1.05 1.10 1.41 1.32
Research & Development to Revenue
16.20 0.47 7.70 1.63 1.29
SG&A to Revenue
1.00 0.09 0.00 0.36 0.32
Stock-Based Compensation to Revenue
0.00 0.00 0.78 0.17 0.14
Income Quality
1.04 1.29 0.86 1.03 0.59
Currency in EUR